Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (121-130 of 167) with videos related to

Pageof 17
Sort By:
Lung Cancer (Amsterdam, Netherlands)|April 9, 2024
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based databaseUmberto Malapelle, Francesco Passiglia, Francesco Pepe, et al.
Frontiers in Oncology|April 21, 2025
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancerAlessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
Clinical Lung Cancer|July 24, 2018
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of CarcinomaMartina Imbimbo, Milena Vitali, Alessandra Fabbri, et al.
Future Oncology (London, England)|January 24, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationaleElisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, et al.
Critical Reviews in Oncology/Hematology|December 1, 2023
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary groupUmberto Malapelle, Alessandro Delle Donne, Fabio Pagni, et al.
The Oncologist|August 21, 2023
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World SettingLaura Bonanno, Martina Lorenzi, Davide Massa, et al.
Histopathology|April 27, 2023
Vascular/epithelial changes as late sequelae after recovery from SARS-COV-2 infection: an in-vivo comparative studyFederica Pezzuto, Francesca Lunardi, Luca Vedovelli, et al.
Clinical Lung Cancer|October 12, 2019
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyAlessandro Dal Maso, Martina Lorenzi, Elisa Roca, et al.
Pageof 17

Showing results (121-130 of 167) with videos related to

Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|April 9, 2024
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based databaseUmberto Malapelle, Francesco Passiglia, Francesco Pepe, et al.
Frontiers in Oncology|April 21, 2025
Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancerAlessandro Dal Maso, Federica Ferrarini, Giovanni Esposito, et al.
Translational Lung Cancer Research|February 11, 2021
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcomeAlberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
Clinical Lung Cancer|July 24, 2018
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of CarcinomaMartina Imbimbo, Milena Vitali, Alessandra Fabbri, et al.
Future Oncology (London, England)|January 24, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationaleElisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, et al.
Critical Reviews in Oncology/Hematology|December 1, 2023
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary groupUmberto Malapelle, Alessandro Delle Donne, Fabio Pagni, et al.
The Oncologist|August 21, 2023
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World SettingLaura Bonanno, Martina Lorenzi, Davide Massa, et al.
Histopathology|April 27, 2023
Vascular/epithelial changes as late sequelae after recovery from SARS-COV-2 infection: an in-vivo comparative studyFederica Pezzuto, Francesca Lunardi, Luca Vedovelli, et al.
Clinical Lung Cancer|October 12, 2019
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid BiopsyAlessandro Dal Maso, Martina Lorenzi, Elisa Roca, et al.
Pageof 17